Home › SEC Filings
SEC Filing Analysis
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| MOLN | PRESS-RELEASE | neutral | 3/10 | Molecular Partners provided a pipeline update for its Radio-DARPin therapeutics, confirming ongoing Phase 1/2a dosing fo | Jul 6, 2026 |
| FDMT | INST-CLUSTER | neutral | 3/10 | The 2026-Q1 institutional cluster for FDMT shows a near-balanced mix of 8 buyers ($32.1M aggregate holdings, +$15.9M add | Jul 5, 2026 |
| MRK | COURT-RULING | neutral | 2/10 | The court granted in part Kaiser's request to take additional depositions of Merck (including a 30(b)(6) deposition on V | Jul 4, 2026 |
| BIOA | COURT-RULING | bullish | 7/10 | The federal district court granted BioAge Labs' motion to dismiss the securities class action lawsuit with prejudice and | Jul 4, 2026 |
| LODE | INST-CLUSTER | neutral | 5/10 | { "summary": "Comstock Inc. (LODE) saw a strong institutional accumulation cluster in Q1 2026, with 10 buyers adding a | Jul 4, 2026 |
| NVO | COURT-RULING | bullish | 5/10 | Novo Nordisk obtained dismissal of an ERISA class action alleging imprudent management of its 401(k) plan. The court fou | Jul 4, 2026 |
| CAPR | COURT-RULING | bullish | 7/10 | The court granted Capricor's request for an expedited briefing schedule on its motion to remand the case back to state c | Jul 3, 2026 |
| ALVO | PRESS-RELEASE | neutral | 4/10 | Alvotech disclosed that a major shareholder, Celtic Lux Holdings (formerly Alvogen Lux Holdings), has pledged 88,940,619 | Jul 3, 2026 |
| MRK | COURT-RULING | neutral | 4/10 | Kaiser Foundation Health Plan, Inc. won a ruling in its lawsuit against Merck & Co., Inc. in the Northern District of Ca | Jul 3, 2026 |
| LLY | COURT-RULING | neutral | 2/10 | A Pennsylvania federal court granted plaintiff's motion to remand a Zyprexa personal-injury/wrongful-death case back to | Jul 3, 2026 |
| UNCY | DEFA14A | neutral | 2/10 | Unicycive Therapeutics filed a DEFA14A (as an 8-K) reporting the results of its 2025 Annual Meeting. All three director | Jul 3, 2026 |
| RDY | 6-K | neutral | 2/10 | Dr. Reddy's filed a routine 6-K disclosing a small equity allotment of 6,730 shares upon exercise of employee stock opti | Jul 3, 2026 |
| GLMD | 6-K | bullish | 7/10 | Galmed Pharmaceuticals consummated the acquisition of Colospan Ltd. on June 22, 2026, paying $3.3M in cash plus up to $2 | Jul 3, 2026 |
| RDHL | 6-K | neutral | 2/10 | RedHill Biopharma filed a 6-K providing notice of its annual general meeting scheduled for July 28, 2026. The agenda inc | Jul 3, 2026 |
| LSBCF | 6-K | bullish | 7/10 | LakeShore Biopharma shareholders voted overwhelmingly (86.2% of votes cast) to approve the merger agreement with Oceanpi | Jul 3, 2026 |
| TRAW | 8-K | neutral | 5/10 | Traws Pharma announced it will resubmit an updated toxicology data package to the UK MHRA in Q3 2026 for tivoxavir marbo | Jul 3, 2026 |
| MLTX | 8-K | bullish | 7/10 | MoonLake announced Week 52 data from Phase 3 VELA program in hidradenitis suppurativa showing 67.2% HiSCR75 and 33.1% Hi | Jul 3, 2026 |
| CANF | 6-K | neutral | 3/10 | Can-Fite announced the publication of a peer-reviewed scientific article in Biomolecules Journal reviewing the therapeut | Jul 3, 2026 |
| TCRX | 8-K | bullish | 6/10 | TScan Therapeutics reported positive initial data from Cohort C of the ALLOHA Phase 1 study for TSC-101, showing 11 of 1 | Jul 3, 2026 |
| MPLT | 8-K | mixed | 6/10 | MapLight Therapeutics announced topline results from the Phase 2 IRIS trial of ML-004 in autism spectrum disorder. The s | Jul 3, 2026 |
| APGE | 8-K | neutral | 5/10 | Apogee Therapeutics entered into an exclusive worldwide license agreement with Paragon Therapeutics for antibodies targe | Jul 3, 2026 |
| ABBV | 8-K | bullish | 7/10 | AbbVie announced the acquisition of Apogee Therapeutics for $135.11 per share in cash, totaling approximately $10.9 bill | Jul 3, 2026 |
| RVMD | 8-K | neutral | 2/10 | Revolution Medicines filed an 8-K announcing the planned retirement of President of R&D Steve Kelsey, effective January | Jul 3, 2026 |
| DARE | 8-K | neutral | 2/10 | Dare Bioscience filed an 8-K under Item 7.01 to furnish a corporate investor presentation dated June 22, 2026, for use i | Jul 3, 2026 |
| GNPX | 8-K | neutral | 2/10 | Genprex announced that the Canadian Intellectual Property Office issued a Notice of Allowance for a patent covering Reqo | Jul 3, 2026 |
| AWHL | 8-K | bearish | 5/10 | CEO Michael Buhle departed Aspira Women's Health on June 17, 2026, with Chairman John Fraser appointed as Interim CEO wh | Jul 3, 2026 |
| NUVB | 144 | bearish | 6/10 | Stacy Markel, an officer of Nuvation Bio, filed a Form 144 on June 23, 2026, indicating intent to sell 125,000 shares of | Jul 3, 2026 |
| NTHI | 424B5 | bearish | 6/10 | NeOnc Technologies filed a 424B5 prospectus to register 555,554 shares for resale by selling stockholder 64K Capital, LL | Jul 3, 2026 |
| KYMR | 144 | neutral | 2/10 | Atlas Venture Fund X, L.P., a venture capital firm and early investor in Kymera Therapeutics, filed a Form 144 notice of | Jul 3, 2026 |
| PTPI | 3 | neutral | 2/10 | Robert Weinstein filed a Form 3 initial statement of beneficial ownership with the SEC, disclosing 636,004 shares of Pet | Jul 3, 2026 |